The Company's lead product candidate, nemvaleukin alfa, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2, while mitigating its hallmark toxicities. The company develops nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab, cutaneous melanoma and advanced solid tumors, as well as engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Cyborg Score Rationale
Clinical-stage company with two potentially registrational trials that faced setbacks in late 2024/early 2025. Company underwent acquisition by XOMA Royalty in December 2025, indicating inability to achieve standalone success as an independent public company.
Top Insights
Lead program (nemvaleukin alfa) faced trial discontinuation: ARTISTRY-7 in platinum-resistant ovarian cancer did not progress to final analysis based on interim overall survival data
Acquired by XOMA Royalty in December 2025 at $2.035/share base price ($36.2M valuation), indicating market loss of confidence
Focused on engineered cytokine therapies for cancer, an emerging immunotherapy category with limited clinical validation at the time of acquisition
Clinical-stage company with no marketed products and multiple programs requiring continued development and capital investment
(February 2025) Interim analysis of ARTISTRY-7 trial in platinum-resistant ovarian cancer showed negative overall survival data, trial did not progress
(June 2024) Nemvaleukin alfa Phase 3 trials reported to be on track with readouts expected in late Q1/early Q2 2025
Open the full interactive Mural Oncology plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.